123
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

The broader prospects for bispecifics in Hodgkin lymphoma

&
Pages 1777-1779 | Received 18 Jul 2022, Accepted 20 Jul 2022, Published online: 03 Aug 2022
 

Author contributions

K.L.C and S.M.A wrote all aspects of this manuscript.

Disclosure statement

S.M.A receives research funding from: Bristol-Myers Squibb, Seattle Genetics, Affimed Therapeutics, Regeneron, Trillium Therapeutics, AI Therapeutics, ADC Therapeutics. All remaining authors declare no competing conflict-of-interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.